All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Mary Jo Lechowicz, Winship Cancer institute of Emory University, Atlanta, US. We asked, How can we address treatment disparities in patients with T-cell lymphoma?
How can we address treatment disparities in patients with T-cell lymphoma?
Lechowicz begins by outlining some reasons for these disparities and stresses the importance of international collaboration. She then discusses social determinants for health and current multi center studies, emphasizing that collaboration and communication are key factors.
The efficacy and safety of the JAK 1/2 inhibitor ruxolitinib in TCL
The pursuit of molecular targets in T-cell lymphomas (TCL) is vital, given their heterogeneous nature and lack of effective treatment in both the frontline and relapsed/refractory...
What does the future of T-cell lymphoma management look like?
During Lymphoma Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Jia Ruan, Weill Cornell Medicine, New York, US. We asked, What does the future of T-cell...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox